2022
Modulators of ASIC1a and its potential as a therapeutic target for age-related diseases
Zhou R, Liang H, Hu W, Ding J, Li S, Chen Y, Zhao Y, Lu C, Chen F, Hu W. Modulators of ASIC1a and its potential as a therapeutic target for age-related diseases. Ageing Research Reviews 2022, 83: 101785. PMID: 36371015, DOI: 10.1016/j.arr.2022.101785.Peer-Reviewed Original ResearchConceptsAcid-sensing ion channel 1aAge-related diseasesTherapeutic targetPotential therapeutic targetMost age-related diseasesIon channel 1aNovel drug targetsEffective drugsMultiple organsPathophysiological processesChannel 1aDiseaseChannel family membersPharmacological propertiesImproved treatmentSuch diseasesTissue degenerationCellular apoptosisTreatmentDrug targetsFamily membersPhysiological functionsUrgent needWorldwide populationIschemia
2018
Necrostatin-1 ameliorates adjuvant arthritis rat articular chondrocyte injury via inhibiting ASIC1a-mediated necroptosis
Chen Y, Zhu C, Zhu F, Dai B, Song S, Wang Z, Feng Y, Ge J, Zhou R, Chen F. Necrostatin-1 ameliorates adjuvant arthritis rat articular chondrocyte injury via inhibiting ASIC1a-mediated necroptosis. Biochemical And Biophysical Research Communications 2018, 504: 843-850. PMID: 30219231, DOI: 10.1016/j.bbrc.2018.09.031.Peer-Reviewed Original ResearchConceptsRat articular cartilageRheumatoid arthritisNec-1Necrostatin-1Potential therapeutic strategyAcid-induced increaseChannel inhibitor amilorideArticular cartilage damageReceptor interacting protein 1Articular cartilageRIP1/RIP3Chondrocyte injuryAA ratsCartilage damageTherapeutic strategiesRA treatmentCartilage injuryPathophysiological processesPsalmotoxin-1Inhibitor necrostatin-1Expression of RIP1Inhibitor amilorideRIP1 inhibitor necrostatin-1Interacting protein 1ASIC1a